Table 2 Characters for non-cancer participants in nine placebo-controlled and standard care-controlled statin trials
Study | Cancer outcome | Relative LDL-c reduction | endpoint LDL-c (mmol/L) | New cancer cases | Number in statin group | Number in control group | New cancer in satin group | New cancer in control group |
|---|---|---|---|---|---|---|---|---|
HPS | CNS, Gastrointestinal, genitourinary, respiratory et al. | 32.35 % | 2.3 | 3493 | 10269 | 10267 | 1749 | 1744 |
AURORA | Not specified | 43 % | 1.1 | 225 | 1389 | 1384 | 107 | 118 |
CARDS | Not specified | below 2.59 mmol/L | 1.99 | 141 | 1428 | 1410 | 69 | 72 |
JUPITER | Not specified | 49 % | 1.42 | 612 | 8901 | 8901 | 298 | 314 |
GDDS | Not specified | 42 % | 1.86 | 83 | 619 | 636 | 39 | 44 |
ALLIANCE | Not specified | 34.30 % | 2.5 | 144 | 1217 | 1225 | 67 | 77 |
PROSPER | Gastrointestinal, genitourinary, respiratory et al. | 34 % | 2.5 | 444 | 2891 | 2913 | 245 | 199 |
LIPS | Gastrointestinal, genitourinary, respiratory, CNS et al. | below 2.59 mmol/L | 2.48 | 32 | 844 | 833 | 14 | 18 |
4S | Gastrointestinal | 35 % | 3.17 | 205 | 2221 | 2223 | 103 | 102 |
TOTAL | 5379 | 29779 | 29792 | 2691 | 2688 |